Skip to content
Search

Latest Stories

Weight-loss injections can cause gallstones, warns pharmacist

An increasing number of patients taking weight-loss injections are having their gallbladders removed, the pharmacist said.

More patients on weight-loss injections undergoing gallbladder removal, warns pharmacist

Weight-loss injections can make bile more sludgy and even lead to the formation of gallstones

GettyImages

A leading pharmacist has raised concerns over a rise in gallbladder issues among individuals using weight-loss injections, particularly Eli Lilly’s Mounjaro (tirzepatide).

Deborah Grayson, a pharmacist and nutritional therapist, shared an alert in a TikTok video, highlighting the potential effects of weight-loss injections on gallbladder health.


“I'm seeing more and more patients taking weight-loss injections who then need their gallbladders removed,” she said.

Grayson, known as The Godmother of Pharmacology, explained how these drugs increased the risk of gallstone formation.

“The injections slow down the flow of bile through the gallbladder and delay emptying by suppressing the release of the hormone that controls it.

“This is one of the key ways in which it works. Unfortunately, this can also mean that in some people, this can make bile more sludgy and even lead to the formation of gallstones,” she warned.

According to Grayson, the risk of gallstone development could be as high as 1 in 10 people taking these drugs.

Deborah Grayson LinkedIn

Eli Lilly has already acknowledged gallbladder-related side effects in its safety warnings for Mounjaro, which is an injectable prescription medicine originally developed to manage blood sugar in adults with type 2 diabetes.

It is also authorised for use in weight loss and weight management in adults aged 18 and over, alongside a reduced-calorie diet and increased physical activity.

“Gallbladder problems have happened in some people who use Mounjaro,” the company said.

The company also listed other serious potential side effects, including:

  • Thyroid tumors, including thyroid cancer
  • Pancreatitis (inflammation of the pancreas)
  • Hypoglycemia (low blood sugar)
  • Severe allergic reactions
  • Kidney failure
  • Serious stomach issues
  • Changes in vision

These problemshave also been associated with Wegovy (semaglutide), produced by Novo Nordisk.

Beware of the risk factors of gallstones

Grayson also highlighted other risk factors that could increase the risk of developing gallstones. These include being women, thyroid disease, menopausal or perimenopausal, and rapid weight loss.

“If any of these apply to you, it's important to look out for the signs that your gallbladder is struggling,” she said.

In a follow-up social media post, Grayson said that high cholesterol and poorly managed blood sugar are also risk factors and warned that “the more of these that apply the greater the risk.”

Symptoms of gallstones

Grayson advises patients taking the injections to be aware of the early warning signs of gallstones or sludgy bile that can lead to the stones forming. These include:

  • Acid reflux
  • Trapped wind and burping
  • Pain below the ribs
  • Left-sided shoulder pain
  • Abdominal pain
  • Diarrhoea or to a lesser extent constipation
  • Pale, greasy floaty stools
  • Bowel urgency

Patients experiencing these symptoms should seek medical advice promptly.

Before using weight loss jabs, it is advisable to inform your healthcare provider about any medical conditions you have and any medications you are taking to help prevent serious side effects.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less